Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Patrys Limited
  6. Summary
    PAB   AU000000PAB9

PATRYS LIMITED

(PAB)
 SummaryChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
0.049 0.048 0.045 0.05 0.05 Last
16470480 8397497 12105870 10905280 4323322 Volume
0.00% -2.04% -6.25% +11.11% 0.00% Change
Estimated financial data (e)
Sales 2019 0,84 M 0,62 M 0,62 M
Net income 2019 -0,41 M -0,30 M -0,30 M
Net cash position 2019 6,47 M 4,75 M 4,75 M
P/E ratio 2019 -65,1x
Yield 2019 -
Sales 2020 0,77 M 0,57 M 0,57 M
Net income 2020 -2,75 M -2,02 M -2,02 M
Net cash position 2020 3,98 M 2,92 M 2,92 M
P/E ratio 2020 -4,68x
Yield 2020 -
Capitalization 90,9 M 66,8 M 66,7 M
EV / Sales 2019 24,0x
EV / Sales 2020 11,5x
Nbr of Employees 10
Free-Float 71,2%
More Financials
Company
Patrys Limited is engaged in the commercialization of its technologies to develop natural human antibody-based therapeutic products for the treatment of cancer. The Company is engaged in conducting research and development activities in the biopharmaceutical sector. The Company's products include PAT-SM6, PAT-LM1 and PAT-SC1. PAT-SM6 is a natural human antibody that binds to multiple types of cancer, including solid... 
More about the company
All news about PATRYS LIMITED
07/26PATRYS' : Drug Improves Pancreatic Cancer Survival in Animal Study
MT
07/25Patrys Limited Announces Preclinical Study in Model of Pancreatic Cancer
CI
07/11Patrys Limited Announces Full Size Deoxymab PAT-DX3 Able to Cross the Blood B..
CI
06/16PATRYS LIMITED : Announces Publication of PAT-DX1 Preclinical Data in JCI - Insi..
BU
06/16PATRYS' : Deoxymab Antibody May Hinder Growth of Brain Cancers, Metastases
MT
06/15Patrys Limited Announces the Publication of New Preclinical Data for Its Deox..
CI
06/09PATRYS : Receives More than $480,000 R&D Tax Refund; Shares Up 3%
MT
05/02PATRYS : Imagion Biosystems to Collaborate on Brain Tumor Imaging and Diagnosis ..
MT
05/02Imagion Biosystems Limited and Patrys Limited Collaborate on New Cancer Imagi..
CI
04/21Patrys Completes PAT-DX1 and Pat-DX3 Pharmacokinetic Studies
CI
03/31PATRYS : Secures US Patent for Anti-Cancer Treatment Deoxymab; Shares Jump 7%
MT
02/19Patrys Limited Reports Earnings Results for the Half Year Ended December 31, ..
CI
02/09Patrys Limited Successfully Establishes PAT-DX1 Stable Cell Line
CI
2020PATRYS LIMITED : RIGHTS ISSUE: 1 new share @ 0.02 AUD for 6 existing shares
FA
2020PATRYS : Adds Full Human Antibody to Deoxymab Portfolio
PU
More news
News in other languages on PATRYS LIMITED

- No features available -

More news
Chart PATRYS LIMITED
Duration : Period :
Patrys Limited Technical Analysis Chart | PAB | AU000000PAB9 | MarketScreener
Technical analysis trends PATRYS LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
James A. Campbell Chief Executive Officer, Director & MD
John Douglas Read Non-Executive Chairman
Valentina Dubljevic Vice President-Scientific & Clinical Development
Michael J. Stork Deputy Chairman & Non-Executive Director
Suzy Jones Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
PATRYS LIMITED108.33%67
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 837